Literature DB >> 440807

Treatment of chlamydial pneumonia of infancy.

M O Beem, E Saxon, M A Tipple.   

Abstract

Infants with untreated chlamydial pneumonia shed Chlamydia trachomatis and are symptomatic for may weeks. We used sulfisoxazole, 150 mg/kg/day, or erythromycin ethyl succinate, 40 mg/kg/day, for approximately 14 days to treat 32 patients with chlamydial pneumonia of infancy, and observed them for nasopharyngeal shedding of C trachomatis and changing clinical status. All infants stopped shedding chlamydiae soon after treatment was started. After treatment, three of the 25 infants tested again became culture positive (but did not have clinical relapse). All infants improved clinically. In 24 (83%) of 29 infants, where the onset of improvement could be times, improvement began within seven days of starting treatment. Progression to complete recovery was observed in 27 of 28 infants examined between two weeks and two months of treatment completion. Neither the existence of concomitant viral infection nor the duration of illness or hospitalization before starting treatment influenced the interval between initiation of treatment and onset of clinical improvement. While these observations do not prove, they are at least compatible with the hypotheses that C trachomatis plays a central etiologic role in this illness and that termination of chlamydial infection is beneficial clinically. Pending the availibility of data from controlled studies, we believe that either of the treatment programs outlined warrant consideration in the clinical management of patients with chlamydial pneumonia of infancy.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 440807

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  14 in total

1.  'Innocent' neonatal inclusion conjunctivitis: parental origins and complications.

Authors:  L V Houck; J A Embil
Journal:  Can Fam Physician       Date:  1981-03       Impact factor: 3.275

2.  Sexually transmitted diseases treatment guidelines, 2015.

Authors:  Kimberly A Workowski; Gail A Bolan
Journal:  MMWR Recomm Rep       Date:  2015-06-05

3.  IgA modulates respiratory dysfunction as a sequela to pulmonary chlamydial infection as neonates.

Authors:  Gopala Krishna Koundinya Lanka; Jieh-Juen Yu; Siqi Gong; Rishein Gupta; Shamimunisa B Mustafa; Ashlesh K Murthy; Guangming Zhong; James P Chambers; M Neal Guentzel; Bernard P Arulanandam
Journal:  Pathog Dis       Date:  2016-01-10       Impact factor: 3.166

4.  Current antibiotic usage II: Aminoglycosides, tetracyclines, erythromycin, vancomycin and sulphonamides.

Authors:  S M Merchant; N P Vithlani
Journal:  Indian J Pediatr       Date:  1986 Mar-Apr       Impact factor: 1.967

Review 5.  Spectrum of human chlamydial infections.

Authors: 
Journal:  West J Med       Date:  1981-09

6.  Chlamydial pneumonia in the low birthweight neonate.

Authors:  A A Attenburrow; C M Barker
Journal:  Arch Dis Child       Date:  1985-12       Impact factor: 3.791

7.  The contribution of interleukin-12/interferon-gamma axis in protection against neonatal pulmonary Chlamydia muridarum challenge.

Authors:  Madhulika Jupelli; Dale M Selby; M Neal Guentzel; James P Chambers; Thomas G Forsthuber; Guangming Zhong; Ashlesh K Murthy; Bernard P Arulanandam
Journal:  J Interferon Cytokine Res       Date:  2010-06       Impact factor: 2.607

8.  Epidemiology and therapy of Chlamydia trachomatis infections.

Authors:  W R Bowie
Journal:  Drugs       Date:  1984-05       Impact factor: 9.546

9.  In vitro and in vivo efficacy of antimicrobials against Chlamydia trachomatis.

Authors:  W R Bowie
Journal:  Infection       Date:  1982       Impact factor: 3.553

10.  Community-acquired pneumonia in children.

Authors:  H Dele Davies
Journal:  Paediatr Child Health       Date:  2003-12       Impact factor: 2.253

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.